Thus, combining a CD19 or BCMA.28ζ CAR with a high-affinity CD38 CCR increased cytokine production, T cell persistence, and in vivo control of tumors, including CD19+ leukemia with <1,000 molecules per cell (44). Here, CD19 is linked to leukemia.